TY - JOUR
T1 - Association of the tau haplotype H2 with age at onset and functional alterations of glucose utilization in frontotemporal dementia
AU - Laws, Simon M.
AU - Perneczky, Robert
AU - Drzezga, Alexander
AU - Diehl-Schmid, Janine
AU - Ibach, Bernd
AU - Bäuml, Josef
AU - Eisele, Tamara
AU - Förstl, Hans
AU - Kurz, Alexander
AU - Riemenschneider, Matthias
PY - 2007/10
Y1 - 2007/10
N2 - Objective: The microtubule-associated protein tau gene (MAPT) contains two extended haplotypes, H1 and H2, which have been linked with sporadic tauopathies. However, there is little evidence as to how these haplotypes may influence the clinical features of the disease. The aim of this study was to investigate the MAPT haplotypes in relation to risk for, and functional alterations of glucose metabolism in, patients with frontotemporal dementia (FTD). Method: The authors investigated MAPT haplotypes in 142 individuals with FTD and 292 comparison subjects. Additionally, in a subset of 41 individuals with FTD and 16 comparison subjects, the authors undertook functional [ 18F]fluorodeoxy-glucose positron emission tomography (PET) imaging. Results: MAPT haplotype distribution did not differ significantly between individuals with FTD and comparison subjects. However, the H2 haplotype was clinically associated with an earlier age at onset of FTD, which presented in a dose-dependent manner. Correspondingly, PET analysis revealed functional differences in glucose utilization patterns between MAPT haplotypes, with H2 carriers having a more pronounced hypometabolism in frontal brain areas than H1 carriers, which could not be accounted for by differences in duration of illness. Conclusions: While the extended MAPT H1 and H2 haplotypes do not appear to confer risk for disease development, the H2 haplotype appears to modify age at onset and functionally shows a more severe decline of glucose utilization in frontal brain areas.
AB - Objective: The microtubule-associated protein tau gene (MAPT) contains two extended haplotypes, H1 and H2, which have been linked with sporadic tauopathies. However, there is little evidence as to how these haplotypes may influence the clinical features of the disease. The aim of this study was to investigate the MAPT haplotypes in relation to risk for, and functional alterations of glucose metabolism in, patients with frontotemporal dementia (FTD). Method: The authors investigated MAPT haplotypes in 142 individuals with FTD and 292 comparison subjects. Additionally, in a subset of 41 individuals with FTD and 16 comparison subjects, the authors undertook functional [ 18F]fluorodeoxy-glucose positron emission tomography (PET) imaging. Results: MAPT haplotype distribution did not differ significantly between individuals with FTD and comparison subjects. However, the H2 haplotype was clinically associated with an earlier age at onset of FTD, which presented in a dose-dependent manner. Correspondingly, PET analysis revealed functional differences in glucose utilization patterns between MAPT haplotypes, with H2 carriers having a more pronounced hypometabolism in frontal brain areas than H1 carriers, which could not be accounted for by differences in duration of illness. Conclusions: While the extended MAPT H1 and H2 haplotypes do not appear to confer risk for disease development, the H2 haplotype appears to modify age at onset and functionally shows a more severe decline of glucose utilization in frontal brain areas.
UR - http://www.scopus.com/inward/record.url?scp=35748941354&partnerID=8YFLogxK
U2 - 10.1176/appi.ajp.2007.06091456
DO - 10.1176/appi.ajp.2007.06091456
M3 - Article
C2 - 17898350
AN - SCOPUS:35748941354
SN - 0002-953X
VL - 164
SP - 1577
EP - 1584
JO - The American journal of psychiatry
JF - The American journal of psychiatry
IS - 10
ER -